Determination of Dextromethorphan and Dextrorphan in Human Urine by High Performance Liquid Chromatography for Pharmacogenetic Investigations

[1]  I. Wainer,et al.  High-performance liquid chromatography assay for simultaneous determination of dextromethorphan and its main metabolites in urine and in microsomal preparations. , 2001, Journal of chromatography. B, Biomedical sciences and applications.

[2]  T. Kamataki,et al.  Analysis of the CYP2D6 gene in relation to dextromethorphan O‐demethylation capacity in a Japanese population , 1999, Clinical pharmacology and therapeutics.

[3]  I. Wainer,et al.  Dextromethorphan as an in vivo probe for the simultaneous determination of CYP2D6 and CYP3A activity. , 1996, Journal of chromatography. B, Biomedical applications.

[4]  E. Perucca,et al.  CYP2D6-related oxidation polymorphism in Italy. , 1994, Pharmacological research.

[5]  T. Ishizaki,et al.  Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese , 1989, Clinical pharmacology and therapeutics.

[6]  M. Relling,et al.  Dextromethorphan and caffeine as probes for simultaneous determination of debrisoquin‐oxidation and N‐acetylation phenotypes in children , 1989, Clinical pharmacology and therapeutics.

[7]  J. Bircher,et al.  Polymorphic dextromethorphan metabolism: Co‐segregation of oxidative O‐demethylation with debrisoquin hydroxylation , 1985, Clinical pharmacology and therapeutics.

[8]  R. Branch,et al.  Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations , 1985, Clinical pharmacology and therapeutics.

[9]  W. Kalow,et al.  Mephenytoin and sparteine pharmacogenetics in Canadian Caucasians , 1984, Clinical pharmacology and therapeutics.

[10]  G. Pfaff,et al.  DEXTROMETHORPHANAS A SAFE PROBE FOR DEBRISOQUINE HYDROXYLATION POLYMORPHISM , 1984, The Lancet.